Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment & Implement...
October 21 2014 - 8:00AM
Business Wire
Company Begins Research of Potential EVD
Application of the Patented Proteins
Immunotech Laboratories, Inc. (OTC PINK: IMMB) (“Immunotech” or
the “Company”) and wholly-owned subsidiary Immunotech Laboratories,
BG (IMMB-BG) today announced that they have successfully completed
negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in
Zimbabwe, to pursue the development of market opportunities related
to the deadly Ebola virus, and to conduct human clinical trials
using the Company's HIV/AIDS and Hepatitis C virus treatment,
Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West
Africa.
With the establishment of an African operation, Immunotech hopes
to fulfill the Company's vision of bringing a therapy based on the
patented Inactivated Pepsin Fraction (IPF) protein developed by
Immunotech for infectious diseases such as HIV/AIDS, Hepatitis C
and a new potential initiative, the Ebola virus. In parts of
Africa, approved experimental treatments are permitted, and with
the Ebola outbreak, Immunotech expects that it can market its
treatment for infectious diseases through the Company’s new
agreement with Uldic.
ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF),
which studies have shown is promising in combination with protease
inhibitors in the treatment of the HIV/AIDS virus. IPF is a
platform technology that can be used to facilitate a broad range of
applications. It is free from neurological, gastrointestinal and
hematological side effects seen in the anti-retrovirals in use
today. IPF has not shown itself to be subject to viral resistance,
and it is cost effective.
The Company says that the immune system has components that bind
and present antigens to cells that are capable of initiating a
response to those antigens. CD1d CD 56 molecules are a family of
highly conserved antigen-presenting proteins that bind lipids and
glycolipids, resulting in activation of natural killer T-cells (NKT
cells) to elicit protective immunity against the immunogen.
Immunotech has isolated IPF which is the most extensively
studied CD 56 ligand to date. The compounds has their ability to
stimulate human NKT-cell lines, secretion of key cytokines such as
IFN- IL 2 and IL-12, and activate autologous dendritic cells, as
well as binding to CD1d and the invariant T-cell receptor. A lead
compound, IPF, emerged from these studies and this protein exhibits
a stronger adjuvant effect in various HIV vaccine platforms in
mice. IPF also provides a protective adjuvant effect with a
candidate HIV and HCV vaccine.
While the majority of the Company’s studies have focused on the
potential of the IPF as a vaccine adjuvant, it is foreseeable that
the compounds could also be used as a potential immuno-therapeutic
to treat infectious diseases.
About Immunotech Laboratories, Inc.Headquartered in
Monrovia, CA, Immunotech Laboratories is a drug development company
committed to the commercialization of its proprietary proteins for
the treatment of debilitating infectious diseases. The Company
strives to become a leader in immuno-therapeutic treatment and the
prevention of HIV/AIDS, Cancer and other immuno-related
disorders.
For more information visit: http://www.immunotechlab.com
Safe Harbor StatementThis news release contains
forward-looking statements that involve risks and uncertainties
associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other
risks described by Immunotech Laboratories, Inc. from time to time
in its periodic reports filed with the SEC. IPF is not approved by
the US Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Immunotech Laboratories
believes that the forward-looking statements and underlying
assumptions contained therein are reasonable, any of the
assumptions could be inaccurate, including, but not limited to, the
ability of Immunotech Laboratories to establish the efficacy of IPF
in the treatment of any disease or health condition, the
development of studies and strategies leading to commercialization
of IPF in the United States, the obtaining of funding required to
carry out the development plan, the completion of studies and tests
on time or at all, and the successful outcome of such studies or
tests. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to
be accurate. In light of the significant uncertainties inherent in
the forward-looking statements included herein, Immunotech
Laboratories or any other person that the objectives and plans of
Immunotech Laboratories will be achieved should not regard the
forward-looking statements as a representation.
Contact:Billy Ray: 770-910-5380Immunotech Laboratories,
Inc.Phone: 818-409-8988Email: ir@immunotechlab.com
Immunotech Laboratories, Inc.Billy Ray,
770-910-5380818-409-8988ir@immunotechlab.com
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Aug 2023 to Aug 2024